| Literature DB >> 30194336 |
Lei Li1, Chang Liu1, Jiayin Yang2, Hong Wu1, Tianfu Wen1, Wentao Wang1, Bo Li1, Lvnan Yan1.
Abstract
Postoperative complication III-V is closely related with hepatectomy-related mortality for hepatocellular carcinoma (HCC) patients. The aim of the study was to investigate the relationship between CONUTS and postoperative complication III-V. 1334 HCC patients who underwent hepatectomy were divided into two groups: high CONUTS group (early postoperative CONUTS ≥ 8, n = 659) and low CONUTS group (early postoperative CONUTS < 8, n = 675). The characteristics and clinical outcomes were compared and analyzed. Risk factors for postoperative complication III-V were evaluated by univariate and multivariate analysis. early postoperative CONUTS showed a good prediction ability for postoperative complication III-V (AUROC = 0.653, P < 0.001), with the cut-off value of 8. The high CONUTS group had higher incidence of postoperative pulmonary complications (12.0% vs 7.9%, P = 0.011), bile leakage (2.6% vs 0.9%, P = 0.018), intra-abdominal hemorrhage (4.9% vs 1.6%, P = 0.001), postoperative liver failure Grade C (3.6% vs 1.0%, P = 0.002), complication III-V (15.6% vs 6.2%, P < 0.001), length of ICU stay > 48 hours (9.4% vs 4.1%, P < 0.001) and mortality in 90 days (2.6% vs 0.4%, P = 0.001), longer period of postoperative hospitalization (10 (8-13) vs 9 (7-11) days, P < 0.001). Multivariable analysis revealed that early postoperative CONUTS ≥ 8 (OR = 2.054, 95%CI = 1.371-3.078, P < 0.001) was independently associated with postoperative complication III-V. Early postoperative CONUTS ≥ 8 was identified as a novel risk factor for postoperative complication III-V, and should be further evaluated as a predictive marker for who are to undergo liver resection.Entities:
Mesh:
Year: 2018 PMID: 30194336 PMCID: PMC6128835 DOI: 10.1038/s41598-018-31714-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1(A) Assessment of undernutrition status by the CONUT score. Ignacio de Ullibarri J. et al. Nutr Hosp[11]. (B) Flow diagram for 1334 consecutive patients who meet the inclusion criteria.
Patient characteristics and postoperative outcomes between patients with high- and low early postoperative CONUTS.
| Parameters | All patients (n = 1334) | High CONUTS group (n = 659) | Low CONUTS group (n = 675) |
|
|---|---|---|---|---|
| Early postoperative CONUTS ≥ 8 | Early postoperative CONUTS < 8 | |||
|
| ||||
| Male, n (%) | 1136 (85.2%) | 547 (83.0%) | 589 (87.3%) | 0.029 |
| Age (years), median (IQR) | 50 (41–60) | 52 (43–60) | 47 (40–58) | 0.004 |
| HBV-DNA >1000 U/mL, n (%) | 436 (32.7%) | 144 (33.7%) | 244 (31.9%) | 0.893 |
| HBV infection (+), n (%) | 1208 (90.6%) | 609 (92.4%) | 599 (88.7%) | 0.054 |
| Child Pugh grade A, n (%) | 1295 (97.1%) | 637 (96.7%) | 658 (97.5%) | 0.374 |
| Lymphocytes (/mm3), median (IQR) | 1.41 (1.10–1.73) | 1.32 (1.05–1.67) | 1.47 (1.17–1.79) | <0.001 |
| Cholesterol (mg/dL), median (IQR) | 4.09 (3.52–4.69) | 3.97 (3.38–4.50) | 4.19 (3.68–4.87) | <0.001 |
| Total bilirubin (umol/L), median (IQR) | 13.6 (10.4–18.6) | 14.2 (10.7–18.8) | 13.1 (10.2–18.3) | 0.026 |
| Albumin (g/L), median (IQR) | 41.1 (38.2–43.8) | 40.3 (37.2–43) | 41.9 (39.2–44.6) | <0.001 |
| INR, median (IQR) | 1.3 (1.2–1.3) | 1.3 (1.2–1.3) | 1.3 (1.2–1.3) | 0.039 |
| Platelet (109/L), median (IQR) | 139 (97–191) | 140 (96–202) | 139 (99–182) | 0.433 |
| AST (U/L), median (IQR) | 42 (30–61) | 44 (32–67) | 39 (29–53) | <0.001 |
| ALT (U/L), median (IQR) | 40 (29–59) | 41 (29–62) | 39 (28–57) | 0.039 |
| CSPH, n (%) | 354 (26.5%) | 179 (27.2%) | 175 (25.9%) | 0.609 |
| Single tumor, n (%) | 1172 (87.9%) | 581 (88.2%) | 591 (87.6%) | 0.738 |
| Total tumor diameter, n (%) | 7.3 ± 3.2 | 7.4 ± 3.0 | 7.2 ± 3.4 | 0.305 |
|
| ||||
| ASA grade III–IV, n (%) | 310 (23.2%) | 153 (23.2%) | 157 (23.3%) | 0.775 |
| Hepatic inflow occlusion | 0.096 | |||
| Total, n (%) | 174 (13.3%) | 92 (14.0%) | 82 (12.1%) | |
| Hemihepatic, n (%) | 586 (43.9%) | 270 (41.0%) | 316 (46.8%) | |
| None, n (%) | 574 (42.8%) | 297 (45.1%) | 277 (41.0%) | |
| Anatomic hepatectomy, n (%) | 797 (59.7%) | 426 (64.6%) | 371 (55.0%) | <0.001 |
| Major liver resection, n (%) | 880 (66.0%) | 448 (67.9%) | 432 (64.0%) | 0.124 |
|
| 0.002 | |||
| Extended left hemi-hepatectomy, n (%) | 30 (2.2%) | 21 (3.2%) | 9 (1.3%) | |
| Extended right hemi-hepatectomy, n (%) | 21 (1.6%) | 9 (1.4%) | 12 (1.8%) | |
| Left hemi-hepatectomy, n (%) | 227 (17.0%) | 112 (17.1%) | 115 (16.9%) | |
| Right hemi-hepatectomy, n (%) | 394 (29.5%) | 221 (33.5%) | 173 (25.6%) | |
| Wedge hepatectomy, n (%) | 212 (15.9%) | 92 (14.0%) | 120 (17.8%) | |
| Segmental hepatectomy, n (%) | 450 (33.7%) | 204 (31.0%) | 246 (36.4%) | |
| Blood loss (mL), median (IQR) | 400 (250–600) | 450 (300–800) | 350 (200–500) | <0.001 |
| Transfusion, n (%) | 333 (25.0%) | 213 (32.3%) | 120 (17.8%) | <0.001 |
|
| ||||
| Microvascular invasion, n (%) | 215 (16.1%) | 105 (15.9%) | 110(16.3%) | 0.882 |
| Differentiation, n (%) | 0.136 | |||
| High | 79 (5.9%) | 43 (6.5%) | 36 (5.3%) | |
| Moderate | 1029 (77.1%) | 493 (74.8%) | 536 (79.4%) | |
| Low | 226 (16.9%) | 123 (15.3%) | 103 (15.3%) | |
| Cirrhosis, n (%) | 791 (59.3%) | 424 (64.3%) | 367 (54.4%) | <0.001 |
| R0-resections, n (%) | 1166 (87.4%) | 565 (85.7%) | 601 (89.0%) | 0.083 |
|
| ||||
| Complication III-V, n (%) | 145 (10.9%) | 103 (15.6%) | 42 (6.2%) | <0.001 |
| ICU stay > 48 hours, n (%) | 90 (6.7%) | 62 (9.4%) | 28 (4.1%) | <0.001 |
| Postoperative hospitalization, (day), median (IQR) | 10 (8–12) | 10 (8–13) | 9 (7–11) | <0.001 |
| Mortality in 90 days, n (%) | 20 (1.5%) | 17 (2.6%) | 3 (0.4%) | 0.001 |
TBIL = total bilirubin, AST = aspartate aminotransferase, ALT = alanine aminotransferase, ALB = serum albumin, PLT = platelet.
INR = International Normalized Ratio, ASA = American Society of Anesthesiologists, CSPH = clinical significant portal hypertension.
MVI = micro-vascular invasion.
Figure 2(A) The receiver operating characteristic curves for immune-nutritional indexes related to postoperative complication III-V. (B) The area under curves, standard error, P-value and 95% Confidence Interval of indexes in predicting complication III-V.
postoperative complications between patients with high- and low early postoperative CONUTS.
| Postoperative complications* | All patients(n = 1334) | High CONUTS group (n = 659) | Low CONUTS group (n = 675) |
|
|---|---|---|---|---|
| Early postoperative CONUTS ≥ 8 | Early postoperative CONUTS < 8 | |||
| Grade I, n (%) | 120 (9.0%) | 60 (9.1%) | 60 (8.9%) | <0.001 |
| Grade II, n (%) | 179 (13.4%) | 101 (15.3%) | 78 (11.6%) | |
| Grade IIIa, n (%) | 97 (7.3%) | 64 (9.7%) | 33 (4.9%) | |
| Grade IIIb, n (%) | 5 (0.4%) | 4 (0.6%) | 1 (0.1%) | |
| Grade IVa, n (%) | 28 (2.1%) | 22 (3.3%) | 6 (0.9%) | |
| Grade IVb, n (%) | 2 (0.1%) | 2 (0.3%) | 0 (0.0%) | |
| Grade V, n (%) | 13 (1.0%) | 11 (1.7%) | 2 (0.3%) | |
| Cardiovascular complications, n (%) | 16 (1.2%) | 8 (1.2%) | 8 (1.2%) | 0.962 |
| Pulmonary complications, n (%) | 132 (9.9%) | 79 (12.0%) | 53 (7.9%) | 0.011 |
| Neurological complication, n (%) | 15 (1.1%) | 9 (1.4%) | 6 (0.9%) | 0.409 |
| Intracable ascites, n (%) | 36 (2.7%) | 18 (2.7%) | 18 (2.7%) | 0.942 |
| Bile leakage, n (%) | 23 (1.7%) | 17 (2.6%) | 6 (0.9%) | 0.018 |
| Intra-abdominal hemorrhage, n (%) | 43 (3.2%) | 32 (4.9%) | 11 (1.6%) | 0.001 |
| #PLF A-B, n (%) | 158 (11.8%) | 65 (9.9%) | 62 (9.2%) | 0.826 |
| #PLF C, n (%) | 31 (2.3%) | 24 (3.6%) | 7 (1.0%) | 0.002 |
*Postoperative complications were classified by Clavien-Dindo classification[21].
#PLF = Posthepatectomy liver failure (ISGLS)[22].
Clinical parameters between patients with and without complication III-V after liver resection.
| Parameters | Postoperative Complication III-V | ||
|---|---|---|---|
| NO (n = 1189) | YES (n = 145) | ||
| Male, n (%) | 1009 (84.86%) | 127 (87.58%) | 0.384 |
| Age (years), median (IQR) | 50 (41–60) | 52 (43–59) | 0.577 |
| HBV-DNA > 1000 U/mL, n (%) | 386 (32.46%) | 50 (34.48%) | 0.625 |
| HBV infection (+), n (%) | 1071 (90.07%) | 137 (94.48%) | 0.175 |
| Child Pugh score, mean (SD) | 5.4 ± 0.5 | 5.6 ± 0.6 | <0.001 |
| Preoperative total lymphocytes (/mm3), median (IQR) | 1.40 (1.10–1.73) | 1.43 (1.12–1.74) | 0.881 |
| Preoperativel cholesterol (mg/dL), median (IQR) | 4.11 (3.54–4.72) | 3.89 (3.23–4.43 | 0.002 |
| Preoperative albumin (g/L), median (IQR) | 41.2 (38.3–43.9) | 39.7 (36.8–42.8) | <0.001 |
| Total bilirubin (umol/L), median (IQR) | 13.6 (10.3–18.6) | 13.9 (11.5–18.6) | 0.285 |
| INR, median (IQR) | 1.3 (1.2–1.3) | 1.3 (1.2–1.3) | 0.707 |
| Platelet (109/L), median (IQR) | 140 (98–193) | 128 (90–182) | 0.106 |
| AST (U/L), median (IQR) | 41 (30–61) | 45 (32–61) | 0.054 |
| ALT (U/L), median (IQR) | 40 (28–59) | 41 (30–60) | 0.69 |
| Early postoperative albumin (g/L), median (IQR) | 30.4 (27.2–33.6) | 27.7 (24.5–30.7) | <0.001 |
| Early postoperative cholesterol (mg/dL), median (IQR) | 254 (208–309) | 202 (159–264) | <0.001 |
| Early postoperative lymphocytes (/mm3), median (IQR) | 820 (590–1130) | 760 (560–1140) | 0.257 |
| Early postoperative CONUTS ≥ 8 | 556 (46.8%) | 103 (71.0%) | <0.001 |
| CSPH, n (%) | 310 (26.1%) | 44 (30.3%) | 0.274 |
| Single tumor, n (%) | 1045 (87.9%) | 127 (87.6%) | 0.893 |
| Total tumor diameter, n (%) | 7.7 ± 3.3 | 7.2 ± 3.2 | 0.099 |
|
| |||
| ASA grade III–IV, n (%) | 270 (22.70%) | 40 (27.58%) | 0.189 |
| Anatomic hepatectomy, n (%) | 719 (60.47%) | 78 (53.79%) | 0.122 |
| Hepatic inflow occlusion | 0.885 | ||
| Total, n (%) | 154 (12.95%) | 20 (13.79%) | |
| Hemihepatic, n (%) | 525 (44.15%) | 61 (42.06%) | |
| None, n (%) | 510 (42.89%) | 64 (44.13%) | |
|
| 0.079 | ||
| Extended left hemi-hepatectomy, n (%) | 28 (2.4%) | 2 (1.4%) | |
| Extended right hemi-hepatectomy, n (%) | 15 (1.3%) | 6 (4.1%) | |
| Left hemi-hepatectomy, n (%) | 205 (17.2%) | 22 (15.2%) | |
| Right hemi-hepatectomy, n (%) | 355 (29.9%) | 39 (26.9%) | |
| Wedge hepatectomy, n (%) | 183 (15.4%) | 29 (20.0%) | |
| Segmental hepatectomy, n (%) | 403 (33.9%) | 47 (32.4%) | |
| Anatomic hepatectomy, n (%) | 719 (60.47%) | 78 (53.79%) | 0.122 |
| Major liver resection, n (%) | 767 (64.50%) | 113 (77.93%) | 0.001 |
| Blood loss (mL), median (IQR) | 400 (200–600) | 500 (300–900) | <0.001 |
| Transfusion, n (%) | 255 (21.4%) | 78 (53.8%) | <0.001 |
| Pathological results | |||
| Microvascular invasion, n (%) | 192 (16.1%) | 23 (15.9%) | 0.93 |
| Differentiation, n (%) | 0.006 | ||
| High | 67 (5.6%) | 12 (8.3%) | |
| Moderate | 933 (78.5%) | 96 (66.2%) | |
| Low | 189 (15.9%) | 37 (25.5%) | |
| Cirrhosis, n (%) | 693 (58.3%) | 98 (67.6%) | 0.039 |
| R0-resections, n (%) | 1056 (88.8%) | 131 (90.3%) | 0.578 |
TBIL = total bilirubin, AST = aspartate aminotransferase, ALT = alanine aminotransferase, ALB = serum albumin, PLT = platelet.
INR = International Normalized Ratio, ASA = American Society of Anesthesiologists, CSPH = clinical significant portal hypertension.
MVI = micro-vascular invasion.
Multivariate analysis of independent risk factors for patient with complication III-V after liver resection.
| Parameters | Model 1 | Model 2 | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Child Pugh score | 0.709 | 0.526–0.955 | 0.024 | 0.742 | 0.549–1.003 | 0.052 |
| Preoperative albumin | 1.005 | 0.965–1.047 | 0.809 | 1.008 | 0.967–1.051 | 0.692 |
| Preoperative cholesterol | 1.106 | 0.941–1.300 | 0.221 | 0.978 | 0.877–1.089 | 0.683 |
| Early postoperative albumin | 1.054 | 1.013–1.097 | 0.009 | |||
| Early postoperative cholesterol | 1.693 | 1.265–2.264 | <0.001 | |||
| Early postoperative CONUTS ≥ 8 | 2.054 | 1.371–3.078 | <0.001 | |||
| Blood loss | 1.000 | 1.000 | 0.395 | 1.000 | 1.000–1.001 | 0.421 |
| Transfusion (Y) | 3.235 | 2.159–4.847 | <0.001 | 3.159 | 2.054–4.859 | <0.001 |
| Major liver resection (Y) | 1.359 | 0.877–2.106 | 0.170 | 1.332 | 0.853–2.081 | 0.207 |
| Cirrhosis (Y) | 1.238 | 0.842–1.820 | 0.277 | 1.256 | 0.850–1.856 | 0.253 |